Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | First-line therapy options in mRCC

Hans Hammers • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab
CheckMate 214

Hans Hammers, MD, PhD, The University of Texas Southwestern, Dallas, TX, discusses how healthcare professionals come to a decision about the appropriate first-line targeted therapy in metastatic renal cell carcinoma (mRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA

More from Hans Hammers

1:19
HIF-2 inhibitors in RCC
Hans Hammers • 13 Feb 2020
Optimizing immunotherapy duration
Hans Hammers • 15 Feb 2020
RADVAX: pembrolizumab plus radiotherapy
Hans Hammers • 15 Feb 2020
1:54
PD-L1 and other biomarkers for renal cell carcinoma
Hans Hammers • 22 Oct 2018

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals